At the end of every year, myriad strategies are announced for the coming year. With investors continuing to love dividends, one strategy that is reviewed every year is the so-called Dogs of the Dow.
KemPharm expects to price its 3 million shares around last Thursday's closing price of $18.88, which would value the entire secondary offering at up to more than $65 million.
Arizona Senator John McCain had argued long and loud about restricting federal contracts to companies that use Russian-built rocket engines in their launch vehicles.
Most of the top firms on Wall Street we cover remain positive on technology, especially the software arena, and a new report from RBC highlight the software stocks the firm likes for next year.
Monday's top analyst upgrades, downgrades and initiations include Avago Technologies, BlackBerry, Ciena, First Solar, Nabors Industries, Rackspace, SunPower, Tiffany and Yelp.
We are approaching the absolute break-even point for oil production, if we haven’t done so already. Then a contraction in supply should translate to a reversal in price.
Yahoo has taken quite a beating in 2015, and the bears are piling up. The September bottom seems to have held for nearly three months now, while sentiment for the stock has yet to…
These 50% to 100% implied upside picks from analysts are generally coming with far more risk than traditional Dow stocks, even if many of these are large cap stocks.
Spot and forward prices for marijuana supplies have not yet experienced the drop in prices that normally comes at this time of year as the annual harvest is brought in.
On December 3, Med-X Inc. filed a Form 1-A: Tier 2 with the U.S. Securities and Exchange Commission to issue 25 million shares of common stock at $0.60 per share. Med-X researches and develops…